Highlights Veru Inc.

Equities

VERU

US92536C1036

Real-time Estimate Cboe BZX Other stock markets 07:45:20 10/05/2024 pm IST			5-day change	1st Jan Change
1.405 ^USD	+2.55%		-12.58%	+97.92%

08/05	Earnings Flash (VERU) VERU Posts Q2 Revenue $4.1M	MT
06/05	HC Wainwright Adjusts Veru Price Target to $3 From $2, Maintains Buy Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (VERU) VERU Posts Q2 Revenue $4.1M	08/05	MT
Veru Inc. Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss	30/04	CI
Veru Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	02/04	CI
Veru Inc. Announces U.S. Food and Drug Administration Clearance of Investigational New Drug Application for its Phase 2b Clinical Study	06/02	CI
Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with Glp-1 Drugs for Weight Loss	08/01	CI
Veru Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	09/12	CI
Veru Inc. Reports Muscle Data from 5 Clinical Studies of Enobosarm	04/23/04	CI
Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication	26/23/26	CI
Veru Inc. Announces Clinical Data from Its Discontinued Phase 3 ARTEST Clinical Trial of Enobosarm Monotherapy	11/23/11	CI
Earnings Flash (VERU) VERU Posts Q3 Revenue $3.3M	10/23/10	MT
Veru Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	10/23/10	CI
Earnings Flash (VERU) VERU Reports Q2 Revenue $6.6M	11/23/11	MT
Veru Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	11/23/11	CI
Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS	04/23/04	CI
Veru Sells Entadfi Business for $20 Million Plus Up to $80 Million From Sales Milestones; Shares Up Pre-Bell	20/23/20	MT
Veru Sets Accord With Afaxys to Offer FC2 Female Condom in US Public Health Centers	19/23/19	MT
Veru Says Preclinical Data Show Sabizabulin Inhibits Poxviruses; Shares Rise	11/23/11	MT
Veru Says Influenza Drug Candidate Showed 'Robust' Anti-Inflammatory Activity in Animal Study	04/23/04	MT
Veru Shares Hit 52-Week Low After FDA Denies Emergency Use For Covid-19 Treatment	04/23/04	DJ
US FDA Denies Emergency Use Authorization for Veru's COVID-19 Drug Candidate Sabizabulin	03/23/03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Veru Inc.

Equities

VERU

US92536C1036

Highlights

Filters